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Abstract
Background: Limited data exist on the economic consequences of implementing tar-
geted therapy (TT) for metastatic renal cell carcinoma (RCC) in a real-world setting.
Objective: To analyze health care and productivity costs for TT implementation in a
national cohort of patients.
Design, setting, and participants: Costsweremeasured per patient per year during a 2-yr
follow-up during 2002–2005 (immunotherapy only) and 2006–2009 (TT implementa-
tion). All Danish patients with a diagnosis code for RCC and a procedure code for TT or
immunotherapywere linked to theDanishNational PatientRegistry (contains information
on all contacts with primary and secondary health sector). Health care and productivity
costs were retrieved from the Danish case-mix system and Coherent Social Statistics,
respectively.Drugcostswere calculated separately fromprocedurecodes andretail prices.
Outcome measurements and statistical analysis: Generalized linear models were used
to analyze costs adjusted for age, gender, and civil status.
Results and limitations: A total of 439 patientswere included for 2006–2009 and 192 for
2002–2005. Comparison of the health care cost per patient per year between 2006–2009
and 2002–2005 revealed lower inpatient costs (s11 899 vs s19 944, adjusted relative
risk [RR] 0.64), higher outpatient costs (s14 308 vs s6209, RR 2.39), lower radiotherapy
costs (s194 vs s633, RR 0.31), higher radiology costs (s676 vs s191, RR 3.73), and
higher separately calculated drug costs (s12 040 vss3103, RR 3.82, all p < 0.001) for the
former. Total health care costs per patient per year did not signiﬁcantly differ (s27 676
vss27 856, RR 1.05, p = 0.5) between the two periods. Income from employment did not
signiﬁcantly differ between 2006–2009 and 2002–2005 (RR 1.11, p = 0.11) and costs
associated with loss of productivity were s7852 and s8265, respectively.
Conclusions: A different pattern of health care costs were observed but total health care
costs per patient per year did not signiﬁcantly differ after implementation of TT for
patients with mRCC.
Patient summary: In this nationwide study, we found changes in the pattern of health
care costs for patients with metastatic kidney cancer after implementation of targeted
therapy compared to an immunotherapy control period; however, total health care costs
and income from employment were without signiﬁcant changes.
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Renal cell carcinoma (RCC) accounts for 2–4% of newly
diagnosed cancers in adults and most cases present in
men >60 yr [1]. The incidence rate is increasing, and
in 2012 there were approximately 338 000 new cases
and 143 000 deaths from kidney cancers worldwide [2,3].
The paradigm shift for cancer treatment with the
discovery of targeted therapy (TT) and immune checkpoint
regulation has introduced several new drugs for patients
with metastatic RCC (mRCC) and additional drugs are
currently in clinical trials. Demographic changes towards an
older population, together with the high costs of new drugs,
represent a potential financial burden on the individual or
on society, depending on the health care system.
Although cost estimates for single-agent therapies have
beenpublished,nationalpopulation-baseddataonhealthcare
costsandproductivitycostsrelatedto implementationofTT in
a real-world setting donot exist [4–14]. In a previous studyby
the Danish Renal Cancer Group (DaRenCa), we assessed
implementationofTTinacompletenationalcohortofpatients
withmRCC and found a shift in treatment pattern towards TT
and a50% increase inoverall survival (OS) for treatedpatients,
whereas the survival rate for untreated patients remained
unchanged [15]. In the present study, we used this national
cohort from 2006–2009 to analyze total health care and
productivity costs after TT implementation incomparison toa
control cohort from 2002–2005 who received immunothera-
py only.WeusedDanish civil registrationnumbers to retrieve
all health care costs, income from employment, and social
transfer income from national registries.
2. Patients and methods
All Danish patients starting ﬁrst-line treatment ofmRCC between January
1, 2006 and December 31, 2010 were identiﬁed from a national registry
(GS-open)and institutionaldatabases. The civil registrationnumberswere
used to extract anonymous data from the National Patient Registry (NPR).
Thenationaldatabase contains informationonall inpatientandoutpatient
contacts with somatic and psychiatric hospitals, including private
hospitals [16]. The information includes administrative data, procedures,
and diagnoses according to International Classiﬁcation of Diseases 10
(ICD-10). All patients were included in the present study if they were
registered with ICD-10 diagnosis code 64.9 for RCC and a procedure code
for interferon-alpha, interleukin-2, 5-ﬂuoruracil, dendritic cell vaccina-
tion, sunitinib, sorafenib, temsirolimus, everolimus, or bevacizumab
between2006 and2009. To compare costs related toTT implementation, a
control treatment cohort was established from January 1, 2002 to
December 31, 2005 via extraction of data for all Danish patients registered
with ICD-10 diagnosis code 64.9 and registered with a procedure code
for ﬁrst-line interferon-alpha, interleukin-2, dendritic cell vaccination, or
5-ﬂuoruracil. Eighteen patients receiving subsequent TT after 2005 were
excluded. The Civil Registrations System was used to control for costs in
thebackgroundpopulationbyrandomlyselectinga control cohort foreach
treatment cohort at a patient/control ratio of 1:4 according to age, gender,
civil status, and place of residence at the time of primary diagnosis.
2.1. Cost estimates
Costs were divided into health care costs and loss of productivity costs
for 2006–2009 compared to 2002–2005. Costs were measured perpatient per year during a 2-yr follow-up period to approach a lifetime
horizon and were adjusted to 2011 prices using the general price index.
All costs were measured in DKK and converted to euro (s1: DKK7.45).
The analysis was from a societal perspective; however, transport and
loss of leisure time for patients and families were not assessed.
Discounting was omitted because the median overall survival was only
14 mo [15].
Costs per patient were also analyzed for the ﬁrst treatment year in a
larger cohort including patients treated in 2010. However, this cohort
could only be followed for 1 yr because retrieval of data from the NPR has
a long lag period, mainly due to validation.
2.2. Health care costs
Health care costs represent the value of resources used on treatment,
care, and rehabilitation in the primary and secondary health sectors.
Since 2000, the NPR has been the basis for payment for hospital
activities from the Danish case-mix system comprising diagnosis-
related group (DRG, inpatient) and Danish outpatient group system
(DAGS) tariffs [17]. Health care costs were calculated from all
hospitalizations and outpatient visits, weighted by use, according to
DRG and DAGS tariffs. Costs for radiology services and radiotherapy
included average costs per patient per year, 1 yr before and in the ﬁrst
2 yr after treatment initiation. Costs for home care, general care, and
rehabilitation were not included.
Immunotherapy andTT are supplied free of charge to patients by the
treating departments, and drug costs are thus included in DRG and
DAGS tariffs. However, these tariffs cover the cost of an average
outpatient/inpatient visit with regard to diagnosis, procedure, man-
agement of adverse events, employers, and average drug costs related
to chemotherapy. TT costs are therefore underestimated. Drug costs
were thus calculated separately from the national pharmaceutical
procurement service (Amgros) prices and use of treatment-speciﬁc
procedure codes. Prices (2011) fromAmgros for one cyclewith standard
doses (low-dose subcutaneous, 70 kg) were s1651 for interleukin-2
combined with interferon-alpha, s4802 for bevacizumab, s3494 for
everolimus, s3573 for sorafenib, s4545 for sunitinib, and s4396 for
temsirolimus [18]. All drug costs within the ﬁrst 2 yr of treatment were
included.
Costs for general practitioners and practicing specialists according to
use and frequency were extracted from the National Health Security and
costs for prescription medicines from the Danish Medicine Agency.
2.3. Productivity costs
Productivity costs represent the value of resources lost due to disease-
related work disability and premature mortality. In this study, we
assessed income from employment and subsequent loss of productivity
costs as the loss of income due to disease-related work disability.
Employment status, income, and social transfer income were extracted
from Coherent Social Statistics. Social transfer incomes include old-age
pension, early retirement, subsistence allowance, and others. They were
derived from public coffers and represents monetary support of
recipients by the taxpayer, but they do not represent a net increase in
societal resources and were therefore not included in productivity costs.
2.4. Statistical analyses
Statistical analysis was performed using SAS 9.3. Costs in euro were
descriptive and not comparable unless adjusted for age, gender, marital
status, and place of residence, as the health care system was used
differently by these groups. Treatment groups were not matched for the
above-mentioned parameters. We used a regression model controlling
for age, gender, marital status, and place of residence to estimate
E U RO P E AN URO LOG Y 6 8 ( 2 0 1 5 ) 5 1 6 – 5 2 2518whether there were signiﬁcant differences in costs. Since the data
include a zero cost for some observations, we used the one-stepmodel as
described by Buntin et al [19]. The model used is a one-step gamma
distributed generalized linear model with various costs on the left-hand
side, and age and a dummy for gender, marital status, and place of
residence on the right-hand side of the regression.
Logistic regression was used to estimate the difference (odds ratio,
OR) in the proportion of patients received the different types of health
care services.
2.5. Ethics
The study was approved by the Danish Health and Medicines Authority,
the Danish Research Ethics Committee, and the Danish Data Protection
Agency.
3. Results
A total of 439 patients with a median age of 61 yr were
identified in the 2006–2009 cohort (TT implementation)
and 192 patients with a median age of 58 yr in the 2002–
2005 cohort (immunotherapy only; Table 1). The two
cohorts were well matched with their corresponding
background population controls according to age, gender,
and civil status.
3.1. Proportion of patients receiving health care and income
In 2006–2009 compared to 2002–2005, a significantly
lower proportion of patients with mRCC received inpatient
services in the first year after treatment initiation (88.4% vs
98.4%; OR 0.15, p = 0.002) adjusted for age, gender, and civil
status (Table 2). Use of prescription medicine and primary
health sector services were similar between the two
periods, but the proportions were higher than their
respective background population controls. In general,
the proportion receiving social transfer income decreased
significantly in 2006–2009 compared to 2002–2005, while
there were no differences in the proportion of patients that
had income from employment.Table 1 – Patient characteristics
2002–2005
Treatment cohort Background
(immunotherapy) control
Number 192 741
Male, n (%) 132 (69) 504 (68)
Married, n (%) 91 (47) 354 (48)
Median age (yr) a 58 58
Age, n (%) a
<30 yr 2 (1) 8 (1)
30–39 yr 6 (3) 24 (3)
40–49 yr 25 (13) 96 (13)
50–59 yr 80 (42) 311 (42)
60–69 yr 72 (38) 273 (37)
70–79 yr 7 (4) 28 (4)
80 yr 0 (0) 0 (0)
a At treatment start.
b First-line treatment regime.3.2. Health care costs
No difference in total health care costs were observed
between 2006–2009 and 2002–2005 (s27 676 vs s27 856;
relative risk [RR] 1.05, 95% CI 0.93–1.18, p = 0.5) per patient
per year during a 2-yr follow-up period adjusted for age,
gender, and civil status (Table 3). A significant change in the
pattern of care was observed, with lower inpatient costs
(s11 899 vs s19 944) and higher outpatient costs (s14 308
vs s6 209) in 2006–2009 compared to 2002–2005 (RR 0.64,
95% CI 0.57–0.72 and RR 2.39, 95% CI 2.11–2.70, respec-
tively; both p < 0.001). Total health care costs per year were
s5 348 352 in 2002–2005 and s12 149 764 in 2006–2009.
We observed significantly higher costs for radiology
services per patient per year, 1 yr before and in the first 2 yr
after treatment initiation, in 2006–2009 compared to 2002–
2005 when adjusted for age, gender, and civil status (both
p < 0.001; Table 4). Radiotherapy costs per patient per year
were reduced to one-third 1 yr before and in the first 2 yr
after treatment initiation in 2006–2009 compared to 2002–
2005 (both p < 0.001).
Separately calculated immunotherapy costs per patient
per year were s1954 in 2006–2009 compared to s3103 in
2002–2005, and TT costs per patient per year were s10 086
in 2006–2009. The total drug costs per patient per year
during a 2-yr period were s12 040 in 2006–2009, which is
significantly higher than the s3103 in 2002–2005 (RR 3.82,
95% CI 3.37–4.33, p < 0.001).
3.3. Productivity costs and social transfer income
Income from employment were s13 147 per patient per
year during a 2-yr period in 2006–2009, compared to
s16 131 in 2002–2005, but there was a trend for higher
income in 2006–2009 (RR 1.11, 95% CI 0.98–1.25, p = 0.11)
when adjusted for age, gender, and civil status (Table 3).
Productivity costs (foregone earnings)weres7852 in 2006–
2009 and s8265 in 2002–2005. There was no difference in
total social transfer income per patient per year between2006–2009
Treatment cohort Background
Targeted therapy b Immunotherapy b control
256 183 1724
180 (70) 118 (65) 1170 (68)
116 (45) 81 (44) 784 (45)
64 59 61
1 (<1) 1 (<1) 8 (<1)
0 (0) 1 (<1) 4 (<1)
24 (9) 25 (14) 196 (11)
58 (23) 67 (37) 494 (29)
101 (39) 79 (43) 710 (41)
64 (25) 9 (5) 273 (16)
8 (3) 1 (<1) 34 (2)
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CI 0.81–1.04, p = 0.2) even though income from individual
social-transfer payment groups was significantly higher in
2002–2005 when adjusted for age, gender, and civil status.
3.4. Extended analysis
An extended analysis was performed for a larger cohort of
570 patients from 2006–2010 with 1-yr follow-up. Total
health care costs per patient in the first treatment yearwere
s44 342 in 2002–2005 ands38 634 in 2006–2010 (RR 0.94,
95% CI 0.80–1.12, p = 0.5) after adjustment for age, gender,
and civil status. Income from employment was 20% higher
(RR 1.20, 95% CI 1.01–1.42, p = 0.036) in 2006–2010
compared to 2002–2005, with no difference in social
transfer income (RR 0.87, 95% CI 0.74–1.04, p = 0.12).
4. Discussion
TT has replaced best supportive care or cytokine treatment
as the standard of care for patients with mRCC in many
countries. However, TT agents are expensive and may
become a financial burden to individuals or society,
depending on the health care system. Most economic
analyses have been performed on clinical trial patients and
the results may not be directly transferable to real-world
settings. Our study is the first to assess health care and
productivity costs after implementation of TT in a national
cohort of patients with mRCC. We used a population-based
design, utilizing individual-level linkage between registries
containing complete data on all hospitalizations including
university hospitals and local hospitals, outpatient services,
inpatient management of adverse events, medicine, health
care utilization, income from employment, and social
transfer income. Our main finding is that total health care
costs per patient per year did not significantly differ after
implementation of TT for patients with mRCC. We
demonstrated changes in expenses between 2006–2009
and 2002–2005, mainly lower inpatient costs, lower
radiotherapy costs, higher radiology service costs, higher
outpatient costs, and higher drug costs. The median OS
was 14 mo in our patient population [15] and the analyses
were performedwith a 2-yr follow-up to approach a lifetime
horizon. Similar findingswere demonstrated in the extended
analysis for 2006–2010with only 1-yr follow-up.Health care
costs per patient per year were higher in the first treatment
year thanduring a 2-yr period because a higher proportion of
patients were still alive and on treatment in the first year,
while more than half of the patient population had died
within the first two treatment years.
The patient numbers in both cohorts were low and the
results should be interpreted with caution. The 2002–2005
cohort was considerable smaller than the 2006–2009
cohort; it is likely that this can be explained by restriction
of immunotherapy to a selected patient population [20],
whilemore real-world patients can beoffered TT [15]. Treat-
ing a higher volume of patients may lower the costs per
patients over time because of improvements in the pattern
of patient care.
Table 3 – Health care costs, income, and productivity costs per metastatic renal cell carcinoma patient per year in the first year and first two years after treatment initiation
Year 1 Year 1 + 2
Annual cost per patient (s) 2006–2009 vs 2002–2005a Annual cost per patient (s) 2006–2009 vs 2002–2005a
2002–2005 2006–2009 RR 95% CI p value 2002–2005 2006–2009 RR 95% CI p value
Patients Control Patients Control Patients Control Patients Control
Health care cost
Outpatient 10 131 339 21 670 902 2.26 1.90–2.69 <0.001 6209 358 14 308 940 2.39 2.11–2.70 <0.001
Inpatient 32 090 918 16 465 1173 0.56 0.47–0.66 <0.001 19 944 946 11 899 1346 0.64 0.57–0.72 <0.001
Prescription medicine 1611 386 1333 462 0.89 0.75–1.05 0.2 1329 382 1078 447 0.84 0.75–0.95 0.005
Primary health sector 510 210 490 299 0.93 0.78–1.10 0.4 374 214 392 303 1.03 0.91–1.16 0.7
Total health care cost 44 342 1853 39 958 2836 0.96 0.81–1.15 0.7 27 856 1900 27 676 3037 1.05 0.93–1.18 0.5
Income from employment 21 147 25 357 17 076 22 004 1.15 0.96–1.36 0.13 16 131 24 396 13 147 20 999 1.11 0.98–1.25 0.11
Productivity costs
Foregone earnings 4210 4928 8265 7852
Social transfer income
Sick pay (public funded) 2223 68 1462 146 0.86 0.72–1.03 0.097 1906 102 1221 158 0.88 0.77–0.99 0.036
Disability pension 1429 1619 942 978 0.39 0.33–0.47 <0.001 1773 1542 1228 973 0.51 0.45–0.58 <0.001
Early retirement 2673 2742 1801 1889 – b 2218 2816 1563 1829 – b
Age pension 1689 1946 5105 6110 – b 1476 2334 4325 6524 0.50 0.41–0.60 <0.001
Other social transfers 1711 1359 782 612 0.32 0.27–0.38 <0.001 1121 1294 514 642 0.34 0.30–0.39 <0.001
Total social transfer income 9725 7733 10 092 9735 0.87 0.73–1.03 0.11 8493 8088 8851 10 126 0.92 0.81–1.04 0.2
RR = adjusted relative risk for 2006–2009 compared to 2002–2005; CI = conﬁdence interval.
a A generalized linear model with a gamma link was used to control for age, gender, and civil status between treated cohorts in 2006–2009 and 2002–2005.
b Insufﬁcient variation in the model.
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Table 4 – Costs of radiology and radiotherapy per metastatic renal
cell carcinoma patient per year 1 yr before and in the first 2 yr
after treatment initiation
Annual cost per patient
(s)
RR a 95% CI p
value a
2002–2005 2006–2009
Radiology
1 yr before 371 810 2.12 1.79–2.53 <0.001
First 2 yr
after
191 676 3.73 3.30–4.23 <0.001
Radiotherapy
1 yr before 278 122 0.35 0.29–0.43 <0.001
First 2 yr
after
633 194 0.31 0.28–0.36 <0.001
RR = adjusted relative risk for 2006–2009 compared to 2002–2005;
CI = conﬁdence interval.
a A generalized linear model with a gamma link was used to control for age,
gender, and marital status.
E U RO P E AN URO L OGY 6 8 ( 2 0 1 5 ) 5 1 6 – 5 2 2 521We analyzed drug costs in a separate analysis because
DRGandDAGSunderestimate theactual costs. In2006–2009,
drug costs were s12 040 per patient per year during a 2-yr
period,which is almost four timeshigher than in 2002–2005.
The lower price of immunotherapy in 2002–2005 compared
to 2006–2009 ismost likely due to a reduction in drug prices,
especially for interleukin-2. It is also possible that patients
were given immunotherapy for a slightly longer period in
2002–2005 because no other treatment options were
available. Adding the actual cost to the total health care cost
would result in drug costs being counted twice, so replacing
thedrugcost calculatedusing theDRG/DAGSsystemwith the
actual drug cost would be misleading. Drug-specific costs
were not calculated because of the risk of bias from patient
selection and improper registration. Drug retail prices were
higher for sunitinib and temsirolimus, and lower for ever-
olimus and sorafenib when compared to prices in the UK,
while prices for sunitinib were lower than American and
Spanish prices [12–14, 21]. One year of first-line treatment
with sunitinib or interferon-alpha was estimated to cost
s25 000–37 000 per patient for the drug only in an Italian
setting according to data from the AVOREN and sunitinib
versus interferon-alpha trials [4,22,23]. Costs were based on
progression-free survival of 11mo,with a price reduction for
the first treatment cycles because of a risk-sharing agree-
ment with the manufacturer. Total drug costs in our study
were considerably lower than predicted costs in the Italian
study and other cost-effectiveness studies [5,13,14]. Our
results may be explained by the real-world setting, in which
the time to treatment failure for first-line treatment is short
(3–5 mo) and two-thirds of the patients do not continue on
second-line treatment [15]. AFinnishstudyassessed the total
health care costs until death (median 11.9 mo) as s32 951
(2005 prices) for 46 patients treated with interferon-alpha
[24]. The costs were lower than our results from 2002–2005,
which can be explained by lack of interleukin-2 administra-
tion and the lack of resource use for some patients.
Income from employment was 20% higher in the larger
treatment cohort from 2006–2010 compared to 2002–
2005; with the lack of difference in social transfer income,this implies that productivity increased in the first
treatment year when adjusted for age, gender, and civil
status. Similar results could not be shown in the 2-yr follow-
up cohort, probably because of a lower patient number. In
addition, the median OS was 14 mo in our patient
population [15] and patients are unlikely to contribute to
the labor market at the end of their life. The differences in
distribution of social transfers in the first year after
treatment initiation may reflect the difference in age
distribution between the two cohorts.
Chiong et al [25] proposed guidelines for treatment of
mRCC in resource-limited settings, andWuet al [8] proposed
drug assistance programs because the generally high health
care cost related to treatment of mRCC is a barrier for equity
in cancer treatment worldwide. Our economic data may not
be transferable to a resource-limited setting as they depend
on similarities in terms of treatment practice, drug costs, and
resource use. However, our results imply that implementa-
tion of new, expensive drugs does not necessary lead to
increased total health care costs per patient when compared
to standardcarebecauseof changes in thepatternof care, and
many real-life patients do not receive the same amount of
treatment as clinical trial patients. Nevertheless, the
increased number of candidate patients for new treatments
will increase the total costs for society.
Limitations of our study are the retrospective design and
DRG/DAGS tariff underestimation of actual costs, as pricing
is based on average patient care, which depends on the
quality of registration. However, our cohorts are larger than
in earlier observational studies [26,27] and selection biases
are reduced due to the population-based design.
5. Conclusions
Different patterns of health care costs were observed after
implementation of TT in patients with mRCC, with lower
inpatient costs, lower radiotherapy costs, higher outpatient
costs, higher radiology costs, and higher medicine costs.
However, total health care costs per patient per year did not
significantly differ after TT implementation.
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